ISPOR POLAND CHAPTERISPOR POLAND CHAPTER

Polish Society of Polish Society of Pharmacoeconomics (PTFe )Pharmacoeconomics (PTFe )

InternationaInternational examplesl examples

Accepted Accepted

multidisciplinarymultidisciplinary

methodologymethodology

PharmacoeconomiPharmacoeconomicscs

inin

PolandPoland

Optimizing pharmacotherapy through rational Optimizing pharmacotherapy through rational drugs managementdrugs management

Pharmacoeconomics in PolandPharmacoeconomics in Poland

RegulationRegulationss

Methodology/Methodology/

StandardizatiStandardizationon

Polish Polish terminologterminolog

yy

Existing Existing resourcesresources

Educational Educational opportunitiesopportunities

REGULATIONSREGULATIONS

1.1. Act on Health Services Financed from Public SourcesAct on Health Services Financed from Public Sources

a)a) Necessity of justyfying proposed priceNecessity of justyfying proposed price

b)b) Evidence on clinical efficiacy, cost- effectiveness and budget impact analysis Evidence on clinical efficiacy, cost- effectiveness and budget impact analysis

(for innovative drugs)(for innovative drugs)

2.2. Act on PricesAct on Prices

3.3. Regulations concerning Health Technology Assessment AgencyRegulations concerning Health Technology Assessment Agency

a)a) Economic evaluation including cost analysisEconomic evaluation including cost analysis

b)b) Influence on financing from public sourcesInfluence on financing from public sources

4.4. Requirements concerning Treatment Programmes financed by Requirements concerning Treatment Programmes financed by

the National Health Fundthe National Health Fund

a)a) Defining cost-endpoint relationshipDefining cost-endpoint relationship

METHODOLOGY/TERMINOLOGYMETHODOLOGY/TERMINOLOGY

1.1. Polish Guidlines for conducting pharmacoeconomic Polish Guidlines for conducting pharmacoeconomic

evaluations (2000) approved by ISPOR Polish evaluations (2000) approved by ISPOR Polish

ChapterChapter

2.2. The Polish Dictionary of Pharmacoeconomics 1st The Polish Dictionary of Pharmacoeconomics 1st

and 2nd editionsand 2nd editions

3.3. Textbooks and manualsTextbooks and manuals

Limit prices for reimbursed drugsLimit prices for reimbursed drugs

The same active substance, different market price.

Generic limit price

Therapeutic limit price

Different active substances, the same effect, different market price.

REIMBURSEMENT SYSTEMREIMBURSEMENT SYSTEM

Fixed charge 70% 50%Basic and supplementary list

ISPOR POLAND CHAPTERISPOR POLAND CHAPTER in in 2005-2006 2005-2006

Organizing the 3rd Scientific Conference of the Polish Society of Organizing the 3rd Scientific Conference of the Polish Society of

Pharmacoeconomics: („Reimbursement systems in EU countries; discussion Pharmacoeconomics: („Reimbursement systems in EU countries; discussion

about activities of the Society members in working groups of ISPOR about activities of the Society members in working groups of ISPOR

1.1. Working on the 4th Scientific Conference of the Polish Society of Working on the 4th Scientific Conference of the Polish Society of

Pharmacoeconomics (focused on : pharmacoeconomics and economic evaluation Pharmacoeconomics (focused on : pharmacoeconomics and economic evaluation

of heath care programs; prof. Paul Kind as a main speaker: “Patient reported of heath care programs; prof. Paul Kind as a main speaker: “Patient reported

outcomes and quality of life”; inviting Czech and Russian ISPOR Chapters outcomes and quality of life”; inviting Czech and Russian ISPOR Chapters

Presidents Presidents

2.2. Creating Student Section within the Polish Society of Pharmacoeconomics with 25 Creating Student Section within the Polish Society of Pharmacoeconomics with 25

members in order to promote interest and awareness about pharmacoeconomics, members in order to promote interest and awareness about pharmacoeconomics,

health outcome research to various disciplines across members of health-related health outcome research to various disciplines across members of health-related

organizations and universities in Poland organizations and universities in Poland

3.3. Educational support of Student Section by PTFE – lecturesEducational support of Student Section by PTFE – lectures

– „„Pharmacoeconomics in Polish perspective”Pharmacoeconomics in Polish perspective”

– „„Health and economics” prof. Tomasz Hermanowski Health and economics” prof. Tomasz Hermanowski

ISPOR POLAND CHAPTERISPOR POLAND CHAPTER in in 2005-2006 2005-2006

1.1. Cooperation with medical societies in educational area – lectures on Cooperation with medical societies in educational area – lectures on

pharmacoeconomics for pharmacoeconomics for relevantrelevant scientific and medical societies scientific and medical societies

2.2. Discussion with representatives of the Ministry of Health about principles of pricing Discussion with representatives of the Ministry of Health about principles of pricing

and reimbursement system in Poland in relation to pharmacoeconomics and reimbursement system in Poland in relation to pharmacoeconomics

3.3. Discussion with the Association of Pharmaceutical Industry in Poland on the Code Discussion with the Association of Pharmaceutical Industry in Poland on the Code

of Marketing Ethics. of Marketing Ethics. Stating an objection against the use of pharmacoeconomic studies as a marketing tool. Stating an objection against the use of pharmacoeconomic studies as a marketing tool.

4.4. Representing the Polish Society of Pharmacoeconomics on the following Representing the Polish Society of Pharmacoeconomics on the following

conferences:conferences: the 7th Congress of European Association for Clinical Pharmacology and Thearpautics”the 7th Congress of European Association for Clinical Pharmacology and Thearpautics”

Lectures about the role of pharmacoeconomics in drug policy,Lectures about the role of pharmacoeconomics in drug policy,

Conference of Quality  Management Center, Cracow,Conference of Quality  Management Center, Cracow,

Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment

process”, Oct. 2006process”, Oct. 2006

participation in experts panel „How clinical trials for new drugs should be financing?”, Oct. participation in experts panel „How clinical trials for new drugs should be financing?”, Oct.

2006 2006